Middle East & Africa Liver Cancer Diagnostics Market

The liver cancer diagnostics market in Middle East & Africa is expected to grow from US$ 382.25 million in 2021 to US$ 575.86 million by 2028. It is estimated to grow at a CAGR of 6.0% from 2021 to 2028.

The early detection and monitoring of the tumor can provide a more effective treatment. Point-of-care (POC) testing allows the patient to have a handheld test that gives the results rapidly. Moreover, no expertise or special knowledge is required, which is vital when carried out in low-resource areas. Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and carries a poor survival rate. Increased understanding of cancer biology and technological advances enabled the identification of many pathological, genetic, and molecular events that drive hepatocarcinogenesis, leading to the discovery of numerous potential biomarkers in this disease.

Some of the biomarkers used for liver cancer are Alpha-Fetoprotein (AFP), Glypican-3, Des-Gamma-Carboxy (Abnormal) Prothrombin (DCP), Gamma-Glutamyl Transferase, and Serum Alpha-1-Fucosidase, among others. A large number of biomarkers have been shown to have potential predictive significance. Hence, this factor will provide huge opportunities for the liver cancer diagnostics market during the projected period.

With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Middle East & Africa Liver cancer diagnostics market at a substantial CAGR during the forecast period.

Middle East & Africa Liver Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

 

Get more information on this report Request Free Sample PDF

Middle East & Africa Liver Cancer Diagnostics Strategic Insights

Strategic insights for the Middle East & Africa Liver Cancer Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Liver Cancer Diagnostics Report Scope

Middle East & Africa Liver Cancer Diagnostics Regional Insights

The geographic scope of the Middle East & Africa Liver Cancer Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Middle East & Africa Liver Cancer Diagnostics Market Segmentation

The Middle East & Africa liver cancer diagnostics market is analyzed on the basis of type, end user, and country. Based on type, the market is segmented into laboratory tests, imaging, endoscopy, biopsy, and others. In 2021, the laboratory tests segment held the largest share of the market, and the imaging segment is expected to register a higher CAGR during the forecast period.

Based on laboratory tests, the market is segmented into blood tests and biomarkers. In 2021, the blood tests segment held a larger market share, and the same segment is expected to register the highest CAGR in the market during the forecast period.

Based on end user, the market is segmented into hospitals and diagnostic laboratories, academic and research institutes, and CRO laboratories. In 2021, the hospitals and diagnostic laboratories segment held the largest share of the market, and the same segment is expected to register a higher CAGR during the forecast period.

Based on country, the Middle East & Africa liver cancer diagnostics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of MEA. In 2021, Saudi Arabia held the largest market share, and it is also expected to grow at the fastest CAGR during the forecast period.

Abbott; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Illumina, Inc.; Koninklijke Philips N.V.; QIAGEN; Siemens Healthineers AG; THERMO FISHER SCIENTIFIC INC.; GE Healthcare; and Perspectum are the leading companies in the Middle East & Africa liver cancer diagnostics market.